141 related articles for article (PubMed ID: 38383261)
1. Long-term follow-up of patients with high-risk facial basal cell carcinoma treated with interferon.
Sánchez V; Carpio E; Fardales VE; Martínez B; Arias AI; Brito E; Bermudez N; Rodríguez Y
An Bras Dermatol; 2024; 99(3):391-397. PubMed ID: 38383261
[TBL] [Abstract][Full Text] [Related]
2. Treatment of basal cell carcinoma with surgical excision and perilesional interferon-α.
Wettstein R; Erba P; Itin P; Schaefer DJ; Kalbermatten DF
J Plast Reconstr Aesthet Surg; 2013 Jul; 66(7):912-6. PubMed ID: 23566745
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy.
Tucker SB; Polasek JW; Perri AJ; Goldsmith EA
J Am Acad Dermatol; 2006 Jun; 54(6):1033-8. PubMed ID: 16713458
[TBL] [Abstract][Full Text] [Related]
4. Interventions for basal cell carcinoma of the skin.
Thomson J; Hogan S; Leonardi-Bee J; Williams HC; Bath-Hextall FJ
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD003412. PubMed ID: 33202063
[TBL] [Abstract][Full Text] [Related]
5. Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma.
Chimenti S; Peris K; Di Cristofaro S; Fargnoli MC; Torlone G
Dermatology; 1995; 190(3):214-7. PubMed ID: 7599384
[TBL] [Abstract][Full Text] [Related]
6. Treatment of aggressive basal cell carcinoma with intralesional interferon: evaluation of efficacy by Mohs surgery.
Stenquist B; Wennberg AM; Gisslén H; Larkö O
J Am Acad Dermatol; 1992 Jul; 27(1):65-9. PubMed ID: 1619079
[TBL] [Abstract][Full Text] [Related]
7. Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC).
Kwon GP; Ally MS; Bailey-Healy I; Oro AE; Kim J; Chang AL; Aasi S; Tang JY
J Am Acad Dermatol; 2016 Jul; 75(1):213-5. PubMed ID: 27317518
[No Abstract] [Full Text] [Related]
8. Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation.
Rodriguez-Vigil T; Vázquez-López F; Perez-Oliva N
J Am Acad Dermatol; 2007 Jan; 56(1):91-5. PubMed ID: 17190625
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of intralesional interferon alfa-2a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma.
Alpsoy E; Yilmaz E; Başaran E; Yazar S
J Dermatol; 1996 Jun; 23(6):394-6. PubMed ID: 8708151
[TBL] [Abstract][Full Text] [Related]
10. Intralesional alfa-2a interferon therapy for basal cell carcinoma.
Doğan B; Harmanyeri Y; Baloğlu H; Oztek I
Cancer Lett; 1995 May; 91(2):215-9. PubMed ID: 7767912
[TBL] [Abstract][Full Text] [Related]
11. Interferon reduces recurrences of basal cell and squamous cell cancers.
Ikić D; Padovan I; Pipić N; Cajkovac V; Kusić Z; Daković N; Gregurek-Novak T; Soldo-Belić A; Spaventi S; Belicza M
Int J Dermatol; 1995 Jan; 34(1):58-60. PubMed ID: 7896491
[TBL] [Abstract][Full Text] [Related]
12. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up.
Roozeboom MH; Aardoom MA; Nelemans PJ; Thissen MR; Kelleners-Smeets NW; Kuijpers DI; Mosterd K
J Am Acad Dermatol; 2013 Aug; 69(2):280-7. PubMed ID: 23566914
[TBL] [Abstract][Full Text] [Related]
13. Treatment of basal cell carcinoma of the nasal pyramid with intralesional interferon alfa-2b.
Fernández-Vozmediano JM; Armario-Hita JC
J Drugs Dermatol; 2010 Apr; 9(4):381-4. PubMed ID: 20514797
[TBL] [Abstract][Full Text] [Related]
14. Interferon therapy for basal cell carcinoma and squamous cell carcinoma.
Ikić D; Padovan I; Pipić N; Knezević M; Djaković N; Rode B; Kosutić I; Belicza M; Cajkovac V
Int J Clin Pharmacol Ther Toxicol; 1991 Sep; 29(9):342-6. PubMed ID: 1937994
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
[TBL] [Abstract][Full Text] [Related]
16. Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib.
Saintes C; Saint-Jean M; Brocard A; Peuvrel L; Renaut JJ; Khammari A; Quéreux G; Dréno B
J Eur Acad Dermatol Venereol; 2015 May; 29(5):1006-9. PubMed ID: 24980899
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Follow-Up Results of Topical Imiquimod Treatment in Basal Cell Carcinoma.
Bostanci S; Kocyigit P; Vural S; Heper AO; Botsali A
Dermatol Surg; 2018 Jan; 44(1):36-41. PubMed ID: 29016542
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for recurrence of facial basal cell carcinoma after surgical excision: A follow-up analysis.
Armstrong LTD; Magnusson MR; Guppy MPB
J Plast Reconstr Aesthet Surg; 2017 Dec; 70(12):1738-1745. PubMed ID: 28579037
[TBL] [Abstract][Full Text] [Related]
19. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
Sekulic A; Migden MR; Lewis K; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Dirix L; Hou J; Yue H; Hauschild A;
J Am Acad Dermatol; 2015 Jun; 72(6):1021-6.e8. PubMed ID: 25981002
[TBL] [Abstract][Full Text] [Related]
20. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
